Drug Rebate

Key facts

Timing

Paid after the sale based on utilization, often quarterly

Statutory examples

Medicaid Drug Rebate Program and Medicare inflation rebates

Federal framework

Anti-Kickback Statute discount safe harbor, 42 CFR 1001.952(h)

Part D rebate rule

The 2020 rule removing safe harbor protection is delayed by law to 2032

What is a drug rebate?

Unlike an upfront invoice discount, a rebate is paid back later, based on utilization data such as claims filled or units dispensed. The pharmacy or wholesaler still transacts at or near list price, and the payer receives money from the manufacturer afterward.

Rebates come in two broad families. Statutory rebates are set by law, such as Medicaid rebates and the Medicare inflation rebates created by the Inflation Reduction Act of 2022. Commercial rebates are negotiated between manufacturers and pharmacy benefit managers, health plans or their rebate aggregators, mostly for brand drugs that compete within a therapeutic class.

Common types of drug rebates

Rebate arrangements usually fall into these categories:

• Medicaid rebates: owed on Medicaid units under Section 1927 of the Social Security Act, based on Average Manufacturer Price and Best Price.
• Medicare inflation rebates: owed when prices of certain Part B and Part D drugs rise faster than inflation.
• Formulary access rebates: paid for placing a drug on a formulary or a preferred tier.
• Market share or performance rebates: higher rates paid when a drug reaches volume or share targets within its class.
• Price protection rebates: paid back to a payer when list price increases exceed a contractual cap.

Why rebates matter

Rebates are the main reason list prices and net prices diverge. Market access and finance teams model rebate liabilities as part of gross-to-net, and a rebate offered for preferred formulary position must be weighed against its possible effect on Medicaid Best Price and other government price calculations.

For patients, rebates usually do not lower cost sharing at the pharmacy counter, because deductibles and coinsurance are commonly calculated on a price closer to list. That gap drives policy debates about passing rebates through at the point of sale. A 2020 HHS rule that would remove Anti-Kickback Statute safe harbor protection for rebates paid to Part D plans and PBMs has never taken effect, and Congress has delayed it to 2032.

Rebate amounts are almost always confidential, so public analysis relies on aggregate disclosures, government reports and indirect benchmarks rather than contract-level data.